Trellus Health PLC - Interim results
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Interim results
Trellus Health® works across the following key commercial verticals: pharmaceutical patient support programs, clinical trial patient recruitment and retention services, and the
Operational highlights (including post-period end)
· Milestone agreement signed with Johnson & Johnson Health Care Systems Inc in
· Granted preferred vendor status by a leading global Contract Research Organisation ('CRO') in
· Renewed Pfizer licensing agreement for IBD digital patient support content in
Financial highlights
· Net cash of
· Average monthly burn further decreased by additional c.10% to
· Adjusted EBITDA* loss of
· Revenue year-to-date is
* Earnings before interest, tax, depreciation and amortisation adjusted for share-based payments
Outlook
· Given the Company's cash runway, the Board intends to explore a possible fundraising over the coming weeks
Dr.
Going Concern and Fundraising
The Group is in the early stages of commercialising its business and has generated revenues of
Given the Company's early stage in commercialisation, the Board believes that a fundraising is the most appropriate course of action to maximise value. Accordingly, the Board confirms its intention to explore a possible fundraising over the coming weeks with the appropriate structure and quantum to be determined. The Company is currently discussing the optimal fundraising strategy with its professional advisers and the Board will provide shareholders with further updates in the coming weeks.
The Directors have taken steps to reduce outgoings and continue to evaluate all commercial options in a way that maximises its value, including ongoing discussions with a number of potential commercial partners. The Directors are optimistic that additional funding can be obtained to enable the Company and the Group to continue in existence for a period of at least 12 months at the date of approval of these financial statement, however, there is no guarantee that sufficient cash inflows from partnerships, an equity or debt fundraising, or other sources of finance will be forthcoming or in the timeframe required-refer to Note 2.
Enquiries:
|
Trellus Health plc |
|
||
|
Dr. |
Via Walbrook PR |
||
|
|
|
||
|
Singers Capital Markets |
|||
|
|
Tel: +44 (0)20 7496 3000 |
||
|
|
|
||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com |
||
|
|
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/ |
||
|
|
+44 (0)7407 804 654
|
||
About Trellus Health® plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.
Trellus Health® also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members
Shares in Trellus Health® were admitted to trading on AIM in
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates', 'expects', 'intends', 'plans', 'believes', 'seeks', 'estimates', and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
CEO STATEMENT
Commercial progress
Our strategic focus continues to concentrate on executing agreements with pharmaceutical companies, clinical trial organizations and healthcare sectors.
Expansion of verticals
The pharmaceutical sector remains a key strategic vertical for the Group. Our collaborative agreement signed with Johnson & Johnson Health Care Systems Inc. ('J&J') in
Our strategy remains focused on expansion into our clinical trial vertical this year. There is a significant, well-defined problem in clinical trials across disease states, CROs and pharma-the difficulty in recruiting and retaining qualified participants for most trials. Industry data indicates that over 50% of participants fail screening in clinical trials, leading to costly delays and inefficiencies in trial execution.
To address this, we have developed Trellus TrialSet™, a proprietary clinical trials solution powered by Trellus Elevate®. Built on the same validated resilience science and digital platform, TrialSet™ is designed to assess and strengthen participant readiness, ensuring that individuals have the resilience, skills, and tools to engage, adhere, and persist throughout the course of a trial. The solution aims to increase the number and quality of referrals from pre-screening to site-based screening, reduce screen failure rates, and improve participant recruitment and retention, ultimately enhancing trial outcomes
Ongoing Business Update
In
Positive outcomes from these health plan members include an 89% increase in resilience-associated behaviours and 78% reporting greater confidence in managing their condition. While the sample size was small, the data demonstrates the clinical utility of Trellus Elevate®, showing its ability to empower individuals to manage both the emotional and physical challenges of their conditions - driving cost savings, improved adherence, and sustainable long-term outcomes.
The Company has also renewed its agreement with Pfizer to license patient support education content for use in Pfizer's IBD digital app. In addition, the licensing agreement with AstraZeneca for their Phase 2 IBD trial is ongoing.
Enhancing the user and partner experience
In the first half of the year, we enhanced the user interface and overall experience, driving increased engagement on the platform. We also achieved SOC 2 Type II recertification, reaffirming our commitment to the highest standards of privacy and security for our partners and their members. Looking ahead, we are beginning the process for GDPR certification to enable program delivery to clients outside
Financial review
During the period, we maintained a strong focus on cash discipline while continuing to execute on our commercial strategy and enhance platform adaptability. Our adjusted EBITDA loss for the period was
As of
Outlook
The Company's clinically proven resilience platform, Trellus Elevate®, is designed to close the gap between behaviour and adherence, driving scalable results across our verticals. By improving engagement, adherence, persistence, recruitment quality, and retention, we deliver stronger ROI for our clients.
Data from our initial programmes and pilot study show promising, real-world impact. By prioritizing the individual, understanding their behaviours, providing tailored support, and addressing their unique challenges, we empower people to stay on treatment plans and become active participants in their own health journey. This leads to better adherence, stronger engagement, and improved outcomes.
Building on this foundation, we are in late-stage discussions with a second global CRO and will update the market in due course across our verticals. Given the Company's early stage in commercialisation, the Board believes that a fundraising is the most appropriate course of action to maximise value. Accordingly, the Board confirms its intention to explore a possible fundraising over the coming weeks, with the appropriate structure and quantum to be determined.
|
Dr. |
|
Chief Executive Officer and Co-Founder |
CONSOLIDATED CONDENSED STATEMENT OF COMPRENSIVE INCOME FOR THE 6 MONTHS ENDED
30 JUNE 2025
|
|
6 Months Ended Unaudited |
6 Months Ended |
Year Ending 2024 Audited |
|
|
US$'000 |
US$'000 |
US$'000 |
|
Continuing operations |
|
|
|
|
Revenue |
295 |
50 |
114 |
|
Administrative expenses |
(3,310) |
(4,104) |
(8,141) |
|
Operating loss |
(3,015) |
(4,054) |
(8,027) |
|
Share based payments |
8 |
7 |
13 |
|
Depreciation and amortisation |
442 |
428 |
865 |
|
EBITDA before share-based payment |
(3,465) |
(3,619) |
(7,149) |
|
Interest received |
18 |
163 |
245 |
|
Loss before taxation |
(2,997) |
(3,891) |
(7,782) |
|
Income tax charge |
- |
- |
- |
|
Loss for the period |
(2,997) |
(3,891) |
(7,782) |
|
Loss per ordinary share attributable to the owners of the parent during the period |
$ |
$ |
$ |
|
Basic and diluted |
(0.02) |
(0.02) |
(0.05) |
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE 6 MONTHS ENDED
|
|
6 months ended |
6 months ended |
Year ended |
|
|
Unaudited |
Unaudited |
Audited |
|
|
US$'000 |
US$'000 |
US$'000 |
|
Loss for the period |
(2,997) |
(3,891) |
(7,782) |
|
Other comprehensive expense: |
|
|
|
|
Currency translation differences |
(72) |
(6) |
35 |
|
Total comprehensive loss for the period |
(3,069) |
(3,897) |
(7,747) |
CONSOLIDATED CONDENSED STATEMENT OF FINANCIAL POSITION AS AT
|
|
As at |
As at |
As at |
|
|
Unaudited |
Unaudited |
Audited |
|
|
US$'000 |
US$'000 |
US$'000 |
|
Assets |
|
|
|
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
6 |
23 |
13 |
|
Intangible assets |
7,351 |
7,926 |
7,616 |
|
Total non-current assets |
7,357 |
7,949 |
7,629 |
|
|
|
|
|
|
Current Assets |
|
|
|
|
Trade and other receivables |
294 |
200 |
165 |
|
Cash and cash equivalents |
1,568 |
8,045 |
4,344 |
|
Total current assets |
1,862 |
8,245 |
4,509 |
|
Total assets |
9,219 |
16,194 |
12,138 |
|
|
|
|
|
|
Equity attributable to owners of the parent |
|
|
|
|
Share capital |
137 |
137 |
137 |
|
Share premium |
43,387 |
43,387 |
43,387 |
|
Other reserve |
246 |
232 |
238 |
|
Foreign currency reserves |
(2,472) |
(2,441) |
(2,400) |
|
Retained earnings |
(32,592) |
(25,704) |
(29,595) |
|
Total equity |
8,706 |
15,611 |
11,767 |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
Trade and other payables |
513 |
583 |
371 |
|
Total liabilities |
513 |
583 |
371 |
|
Total equity and liabilities |
9,219 |
16,194 |
12,138 |
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE 6 MONTHS ENDED
|
|
Share Capital |
Share Premium |
Foreign Currency Reserve |
Other reserves |
Retained earnings |
Total |
|
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
|
|
|
|
|
|
|
|
At |
137 |
43,387 |
(2,435) |
225 |
(21,813) |
19,501 |
|
Comprehensive income |
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(3,891) |
(3,891) |
|
Other comprehensive expenses |
|
|
|
|
|
|
|
Currency translation differences |
- |
- |
6 |
- |
- |
6 |
|
Total comprehensive expense |
- |
- |
6 |
- |
(3,891) |
(3,885) |
|
Transactions with owners |
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
7 |
- |
7 |
|
Total contributions by and distributions to owners |
- |
- |
- |
7 |
- |
7 |
|
At |
137 |
43,387 |
(2,429) |
232 |
(25,704) |
15,623 |
|
Comprehensive income |
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(3,891) |
(3,891) |
|
Other comprehensive expenses |
|
|
|
|
|
|
|
Currency translation differences |
- |
- |
29 |
- |
- |
(29) |
|
Total comprehensive expense |
- |
- |
29 |
- |
(3,891) |
(3,862) |
|
Transactions with owners |
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
6 |
- |
6 |
|
Total contributions by and distributions to owners |
- |
- |
- |
6 |
- |
6 |
|
At |
137 |
43,387 |
(2,400) |
238 |
(29,595) |
11,767 |
|
Comprehensive income |
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
|
(2,997) |
|
Other comprehensive expenses |
|
|
|
|
|
|
|
Currency translation differences |
- |
- |
(72) |
- |
- |
(72) |
|
Total comprehensive expense |
- |
- |
(72) |
- |
(2,997) |
(3,069) |
|
Transactions with owners |
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
8 |
- |
8 |
|
Total contributions by and distributions to owners |
- |
- |
(72) |
8 |
- |
8 |
|
At |
137 |
43,387 |
(2,472) |
246 |
(32,592) |
8,706 |
|
|
|
|
|
|
|
|
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS FOR THE 6 MONTHS ENDED
|
|
6 months ended |
6 months ended |
Year ended to |
|
|
Unaudited |
Unaudited |
Audited |
|
|
US$'000 |
US$'000 |
US$'000 |
|
Cash flow from operating activities |
|
|
|
|
Loss before income tax |
(3,015) |
(4,054) |
(8,027) |
|
Adjustments for |
|
|
|
|
- Depreciation, amortisation and impairment |
442 |
428 |
865 |
|
- Share-based payments |
8 |
7 |
13 |
|
- Foreign exchange |
|
(1) |
- |
|
Changes in working capital |
|
|
|
|
- Trade and other receivables |
(129) |
(37) |
(2) |
|
- Trade and other payables |
142 |
(203) |
(415) |
|
Interest received |
18 |
163 |
245 |
|
Net cash used in operating activities |
(2,534) |
(3,697) |
(7,321) |
|
Cash flow from investing activities |
|
|
|
|
Internally generated intangible assets |
(170) |
(419) |
(540) |
|
Net cash used in investing activities |
(170) |
(419) |
(540) |
|
Cash flow from financing activities |
|
|
|
|
Net proceeds from issue of ordinary shares |
- |
- |
- |
|
Net cash generated from financing activities |
- |
- |
- |
|
Net decrease in cash and cash equivalents |
(2,704) |
(4,116) |
(7,861) |
|
Cash and cash equivalents at beginning of period |
4,334 |
12,166 |
12,166 |
|
Exchange gain/(loss) on cash and cash equivalents |
(72) |
(5) |
39 |
|
Cash and cash equivalents at end of period |
1,568 |
8,045 |
4,344 |
NOTES FORMING PART OF THE INTERIM FINANCIAL STATEMENTS
1. General information and basis of presentation
Trellus Health plc is a public limited company incorporated in the
The principal activity of Trellus Health PLC (the "Company") is the delivery of resilience-driven care for complex chronic conditions.
The Group's principal activity is that of delivery of resilience-driven care for complex chronic conditions.
Basis of preparation
The financial information in these interim results is that of the holding company and all of its subsidiaries and are unaudited. It has been prepared in accordance with the recognition and measurement requirements of International Financial Reporting Standards as adopted for use in the
The presentation currency of the Group is United States Dollars ("USD" or "US$") and this is the currency of the primary economic environment that the main business operates in.
Certain statements in this announcement constitute forward-looking statements. Any statement in this announcement that is not a statement of historical fact including, without limitation, those regarding the Company's future expectations, operations, financial performance, financial condition and business is a forward-looking statement. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks and uncertainties include, amongst other factors, changing economic, financial, business or other market conditions. These and other factors could adversely affect the outcome and financial effects of the plans and events described in this announcement and the Company undertakes no obligation to update its view of such risks and uncertainties or to update the forward-looking statements contained herein. Nothing in this announcement should be construed as a profit forecast.
The financial information presented herein does not constitute full statutory accounts under Section 434 of the Companies Act 2006 and was not subject to a formal review by the auditors. Comparative figures in the Interim Report for the year ended
These interim accounts have not been prepared in accordance with IAS 34, 'Interim financial reporting'. They have been prepared under AIM Rules of
2. Summary of significant accounting policies
The accounting policies applied by the Group in this financial information are the same as those applied by the Group in its financial statements for the period ended
The principal accounting policies adopted in the preparation of the historical financial information of the Company, have been applied consistently to the period presented.
Going Concern
The Group is in the early stages of commercialising its business and generated revenues of
In considering the appropriateness of this basis of preparation, the Directors have prepared financial forecasts and projections for the Group for a minimum of 12 months from the date of the approval of these financial statements. There are considerable uncertainties, particularly in relation to the quantum and timing of cash receipts from revenue, especially revenue from anticipated contracts. Those financial forecasts and projections have, therefore, considered sensitivities in relation to both quantum and timing of receipts and costs.
The Directors have taken steps to reduce outgoings and continue to evaluate all commercial options in a way that maximises its value, including ongoing discussions with a number of potential commercial partners and discussions with professional advisers in relation to fund raising options.
Having taken into account the information and estimates available at the date of approval of these financial statements, the Directors consider that the Group will require additional funding before
The Directors are optimistic that additional funding can be obtained to enable the Company and the Group to continue in existence for a period of at least 12 months at the date of approval of these financial statements however, there is no guarantee that sufficient cash inflows from partnerships, equity fundraising or other sources will be forthcoming, or in the timeframe required. This represents a material uncertainty in relation to the funding arrangements of the Group which may result in the Company and the Group not being a going concern.
If the Directors are unable to secure sufficient funding they could be forced to take all necessary steps to reduce outgoings and/or take other actions which could include the sale of assets or winding up of the company.
3. Income tax
The Group has no provision for corporation tax due to tax losses incurred since incorporation. The Group has incurred indefinitely available tax losses of approximately
4. Loss per share
Basic loss per share is calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the period.
Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding assuming conversion of all dilutive potential ordinary shares. The Company has one category of dilutive potential ordinary share, being share options. Currently the share options are anti- dilutive.
|
|
6 months ended |
6 months ended |
Year ended |
|
|
Unaudited |
Unaudited |
Audited |
|
|
US$'000 |
US$'000 |
US$'000 |
|
Loss attributable to owners of the parent |
(2,997) |
(3,891) |
(7,782) |
|
|
|
|
|
|
|
Number |
Number |
Number |
|
Weighted average number of ordinary shares in issue |
161,508,333 |
161,508,333 |
161,508,333 |
|
|
|
|
|
|
|
US$ |
US$ |
US$ |
|
Basic loss per share |
(0.02) |
(0.02) |
(0.05) |
5. Intangible Fixed Assets
|
|
Software Development costs US$'000 |
Licence costs
US$'000 |
Total
US$'000 |
|
Cost |
|
||
|
On |
9,061 |
453 |
9,514 |
|
Additions |
419 |
- |
419 |
|
Foreign currency difference |
- |
- |
|
|
At |
9,480 |
453 |
9,933 |
|
Additions |
122 |
- |
122 |
|
Foreign currency difference |
- |
(4) |
(4) |
|
At |
9,602 |
449 |
10,051 |
|
Additions |
170 |
- |
170 |
|
At |
9,772 |
4449 |
10,221 |
|
|
|
|
|
|
Depreciation |
|
|
|
|
On |
(1,507) |
(84) |
(1,591) |
|
Charge for the period |
(395) |
(21) |
(416) |
|
Impairment Charges |
- |
- |
- |
|
At |
(1,902) |
(105) |
(2,007) |
|
Charge for the period |
(407) |
(21) |
(428) |
|
At |
(2,309) |
(126) |
(2,435) |
|
Charge for the period |
(414) |
(21) |
(435) |
|
At |
(2,723) |
(147) |
(2,870) |
Net Book Value
|
|
7,578 |
348 |
7,926 |
|
|
7,293 |
323 |
7,616 |
|
|
7,049 |
302 |
7,351 |
6. Dividends
No dividends to shareholders of the holding company were provided or paid during the six months to
7. Events after the reporting date
There have been no events subsequent to the period end that require disclosure in these financial statements.
8. Related party transactions
The amount owed to
9. Availability of this announcement
This announcement is available from the Company's website, https://trellushealth.com/. If you would like to receive a hard copy of the interim report, please contact the Trellus Health plc's investor relation team (Walbrook PR) on +44 (0)20 7933 8780 or trellus@walbrookpr.com to request a copy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE